M. McClung

发表

Urinary calcium excretion at extremes of sodium intake in normal man.

F. Luft, W. Bennett, D. McCarron, 1981, American journal of nephrology.

Prevention of bone loss with alendronate in postmenopausal women under 60 years of age.

C. Christiansen, P. Ross, C. Chilvers, 1998 .

Quality control of DXA instruments in multicenter trials

M. McClung, K. Faulkner, K. Faulkner, 2005, Osteoporosis International.

M. McClung, 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Comparison of proximal femur and vertebral body strength improvements in the FREEDOM trial using an alternative finite element methodology.

H. Genant, P. Zysset, K. Engelke, 2015, Bone.

Comparison of bone densitometry of the phalanges, distal forearm and axial skeleton in early postmenopausal women participating in the EPIC study

P. Ross, M. McClung, P. Ravn, 2005, Osteoporosis International.

Bilateral comparison of femoral bone density and hip axis length from single and fan beam DXA scans

H. Genant, M. McClung, H. Genant, 2004, Calcified Tissue International.

Monthly Oral Ibandronate Therapy in Postmenopausal Osteoporosis: 1‐Year Results From the MOBILE Study

Dieter Felsenberg, C. Cooper, J. Reginster, 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

P Geusens, H Zippel, P. Geusens, 2001, The New England journal of medicine.

Denosumab for prevention of fractures in postmenopausal women with osteoporosis.

Claus Christiansen, Cesar Libanati, Michael R McClung, 2009, The New England journal of medicine.

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS-2020 UPDATE.

N. Watts, Rachel Pessah-Pollack, N. Binkley, 2020, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Bisphosphonates and osteonecrosis of the jaw.

N. Watts, J. Bilezikian, S. Greenspan, 2006, Annals of internal medicine.

Low Body Mass Index Is an Important Risk Factor for Low Bone Mass and Increased Bone Loss in Early Postmenopausal Women

C. Christiansen, R. Wasnich, D. Hosking, 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Late skeletal effects of early menopause.

M. McClung, 2015, Menopause.

24 – Nonpharmacologic Therapy

M. McClung, 1999 .

Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate

N. Freemantle, M. McClung, D. Kendler, 2011, Osteoporosis International.

Pharmacologic therapy for the treatment and prevention of osteoporosis.

M. McClung, B. McClung, 2001, The Nursing clinics of North America.

The rate of bone mineral loss in normal men and the effects of calcium and cholecalciferol supplementation.

E. Orwoll, S. Oviatt, L. Deftos, 1990, Annals of internal medicine.

CHAPTER 60 – Who Should Be Screened: Who Should Be Treated?

M. McClung, 2008 .

Lebanese guidelines for osteoporosis assessment and treatment: who to test? What measures to use? When to treat?

G. Fuleihan, M. McClung, H. Awada, 2005, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, dose-finding studies.

J. Gallagher, M. McClung, D. Baylink, 2001, The Journal of clinical endocrinology and metabolism.

Prevention of Bone Loss With Tibolone in Postmenopausal Women: Results of Two Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Studies

J. Gallagher, M. McClung, D. Baylink, 2002 .

Perspectives on the non-invasive evaluation of femoral strength in the assessment of hip fracture risk

M. Bouxsein, C. Glüer, M. McClung, 2020, Osteoporosis International.

Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fracture

J. Adachi, E. Franek, M. McClung, 2012, Menopause.

Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial.

J. S. San Martin, P. Miller, M. Peacock, 2011, The Journal of clinical endocrinology and metabolism.

A multicenter study of the influence of fat and lean mass on bone mineral content: evidence for differences in their relative influence at major fracture sites. Early Postmenopausal Intervention Cohort (EPIC) Study Group.

P. Ross, J. Davis, R. Wasnich, 1996, The American journal of clinical nutrition.

Osteoanabolic therapy for osteoporosis in women

M. McClung, A. L. Clark, 2021, Climacteric : the journal of the International Menopause Society.

Romosozumab for the treatment of osteoporosis

M. McClung, 2018, Osteoporosis and sarcopenia.

Western Osteoporosis Alliance Clinical Practice Series: Evaluating the Balance of Benefits and Risks of Long-Term Osteoporosis Therapies.

P. Miller, M. McClung, E. Lewiecki, 2017, The American journal of medicine.

Turnover : Six-Year Results of a Phase 2 Clinical Trial Effect of Denosumab on Bone Mineral Density and Biochemical Markers of Bone

M. Peacock, M. McClung, E. Lewiecki, 2011 .

Fracture risk remains reduced one year after discontinuation of risedronate

N. Watts, A. Grauer, A. Chines, 2008, Osteoporosis International.

Osteopenia: To Treat or Not To Treat?

M. McClung, 2005, Annals of Internal Medicine.

Parathyroid Hormone for the Treatment of Osteoporosis

M. McClung, 2004, Obstetrical & gynecological survey.

Use of highly potent bisphosphonates in the treatment of osteoporosis

M. McClung, 2003, Current osteoporosis reports.

Clinical utility of anti-sclerostin antibodies.

M. McClung, 2017, Bone.

American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendations.

N. Watts, J. Bilezikian, M. Kleerekoper, 2010, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Response to: Comment on: “Denosumab Rapidly Increases Cortical Bone in Key Locations of the Femur: A 3D Bone Mapping Study in Women With Osteoporosis”

Graham M. Treece, Jacques P. Brown, A. Gee, 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Improvements in hip trabecular, subcortical, and cortical density and mass in postmenopausal women with osteoporosis treated with denosumab.

H. Genant, T. Fuerst, K. Engelke, 2013, Bone.

Pharmacologic intervention for prevention of fractures in osteopenic and osteoporotic postmenopausal women: Systemic review and meta-analysis

C. Cooper, J. Kanis, E. McCloskey, 2020, Bone reports.

Efficacy and Safety of Osteoporosis Treatment

M. McClung, 2018, Pocket Reference to Osteoporosis.

Proceedings of the 2016 Santa Fe Bone Symposium: New Concepts in the Management of Osteoporosis and Metabolic Bone Diseases.

J. Shepherd, J. Bilezikian, P. Miller, 2017, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Other Safety Concerns

M. McClung, 2016 .

Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday.

D. Bauer, P. Miller, M. McClung, 2013, The American journal of medicine.

The clinical and epidemiologic consequences of redefining treatment criteria: who should be treated?

M. McClung, 2009, Salud publica de Mexico.

Role of RANKL inhibition in osteoporosis

M. McClung, 2007, Arthritis research & therapy.

Yearly zoledronic acid in postmenopausal osteoporosis.

M. McClung, R. Karam, J. Camm, 2007, The New England journal of medicine.

Comparison of Weekly Treatment of Postmenopausal Osteoporosis with Alendronate Versus Risedronate Over Two Years

D. Kiel, M. Hochberg, K. Saag, 2006 .

Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years.

D. Kiel, M. Hochberg, K. Saag, 2006, The Journal of clinical endocrinology and metabolism.

Prevention of postmenopausal bone loss: six-year results from the Early Postmenopausal Intervention Cohort Study.

C. Christiansen, P. Ross, D. Hosking, 2004, The Journal of clinical endocrinology and metabolism.

Pathogenesis of osteoporotic hip fractures.

M. McClung, 2003, Clinical cornerstone.

Alendronate Improves Bone Mineral Density in Elderly Women with Osteoporosis Residing in Long-Term Care Facilities

T. Schnitzer, D. Schneider, P. Miller, 2002, Annals of Internal Medicine.

American Association of Clinical Endocrinologists 2001 Medical Guidelines for Clinical Practice for the Prevention and Management of Postmenopausal Osteoporosis.

H. Rodbard, N. Watts, R. Recker, 2001, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS 2001 MEDICAL GUIDELINES FOR CLINICAL PRACTICE FOR THE PREVENTION AND MANAGEMENT OF POSTMENOPAUSAL OSTEOPOROSIS Osteoporosis Task Force Chairmen

R. Recker, R. Lindsay, J. Bilezikian, 2001 .

Bisphosphonates in osteoporosis: recent clinical experience

M. McClung, 2000, Expert opinion on pharmacotherapy.

Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group.

P. Sambrook, J. Rodriguez-Portales, G. Fuleihan, 2000, The Journal of clinical endocrinology and metabolism.

Therapy for fracture prevention.

M. McClung, 1999, JAMA.

Alendronate and EstrogenProgestin in the Long-Term Prevention of Bone Loss: Four-Year Results from the Early Postmenopausal Intervention Cohort Study: A Randomized, Controlled Trial

C. Coupland, M. McClung, P. Ravn, 1999, Annals of Internal Medicine.

Alendronate Prevents Postmenopausal Bone Loss in Women without Osteoporosis: A Double-Blind, Randomized, Controlled Trial

J. Eisman, M. McClung, P. Ravn, 1998, Annals of Internal Medicine.

Evidence that increased calcium intake does not prevent early postmenopausal bone loss.

P. Ross, D. Hosking, M. McClung, 1998, Clinical therapeutics.

Cancel the denosumab holiday

M. McClung, 2016, Osteoporosis International.

Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene

S. Cummings, E. Siris, M. McClung, 2006, Menopause.

Proceedings of the 2021 Santa Fe Bone Symposium: Advances in the Management of Osteoporosis and Metabolic Bone Diseases.

P. Anderson, J. Bilezikian, P. Miller, 2021, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Using Osteoporosis Therapies in Combination

M. McClung, 2017, Current Osteoporosis Reports.

Controversies in osteoporosis management: concerns about bisphosphonates and when are "drug holidays" required?

M. McClung, 2013, Clinical obstetrics and gynecology.

Diagnosis and management of osteoporosis in postmenopausal women: clinical guidelines. International Committee for Osteoporosis Clinical Guidelines.

R. Rizzoli, R. Eastell, P. Delmas, 1999, Clinical therapeutics.

Recommendations for estrogen and progestogen use in peri-and postmenopausal women: October 2004 position statement of The North American Menopause Society.

M. Stefanick, P. Schwartz, M. McClung, 2004, Menopause.

Western Osteoporosis Alliance Clinical Practice Series: Treat-to-Target for Osteoporosis.

P. Miller, M. McClung, E. Lewiecki, 2019, The American journal of medicine.

How to Interpret Surrogate Markers of Efficacy in Osteoporosis

M. Hochberg, C. Rosen, M. McClung, 2005 .

Bone safety with risedronate: histomorphometric studies at different dose levels and exposure

R. Recker, M. McClung, P. Chavassieux, 2014, Osteoporosis International.

Bisphosphonate therapy: how long is long enough?

M. McClung, M. McClung, 2015, Osteoporosis International.

A Novel Monthly Dosing Regimen of Risedronate for the Treatment of Postmenopausal Osteoporosis: 2-Year Data

P. Delmas, R. Recker, C. Benhamou, 2012, Calcified Tissue International.

New management options for osteoporosis with emphasis on SERMs

M. McClung, McClung Mr, 2015, Climacteric : the journal of the International Menopause Society.

Understanding and communicating the benefits and risks of denosumab, raloxifene, and teriparatide for the treatment of osteoporosis.

D. Bauer, P. Miller, M. McClung, 2014, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Effect of raloxifene after recombinant teriparatide [hPTH(1–34)] treatment in postmenopausal women with osteoporosis

D. Felsenberg, G. Dalsky, J. S. San Martin, 2007, Osteoporosis International.

How does raloxifene reduce fracture risk?

M. McClung, 2002, Menopause.

Tooth counts do not predict bone mineral density in early postmenopausal Caucasian women. EPIC study group.

D. Hosking, M. McClung, C. Chilvers, 1998, International journal of epidemiology.

Densitometry of the radius using single and dual energy absorptiometry

M. McClung, K. Faulkner, K. W. Gaither, 1994, Calcified Tissue International.

Osteoporosis: An Overview

P. Miller, M. McClung, S. Papapoulos, 2018 .

Histomorphometric effects of calcium or calcium plus 25‐hydroxyvitamin D3 therapy in senile osteoporosis

R. Recker, R. Weigel, E. Orwoll, 1989, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

A phase 2 study of MK-5442, a calcium-sensing receptor antagonist, in postmenopausal women with osteoporosis after long-term use of oral bisphosphonates

M. McClung, J. McGinnis, A. Santora, 2015, Osteoporosis International.

Chronic intermittent cyclical administration of tiludronate in postmenopausal osteoporosis: report of two multicenter studies in 2136 patients

H. Genant, J. Eisman, R. Recker, 1998 .

Bone Densitometry in Osteoporosis Care

M. McClung, 2003 .

Assessing Bone Mass by X-ray Absorptiometry: The WHO Definition of Osteoporosis

M. McClung, 2000 .

Prediction of fracture risk. I: Bone density.

P. Miller, M. McClung, 1996, The American journal of the medical sciences.

Osteoporosis update from the 2010 santa fe bone symposium.

R. Marcus, N. Watts, S. Khosla, 2011, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Future Therapies

M. McClung, 2018, Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism.

Sclerostin antibodies in osteoporosis: latest evidence and therapeutic potential

M. McClung, 2017, Therapeutic advances in musculoskeletal disease.

Emerging Therapies for Osteoporosis

M. McClung, 2015, Endocrinology and metabolism.

Romosozumab in postmenopausal women with osteopenia.

A. Grauer, M. McClung, 2014, The New England journal of medicine.

Preventing postmenopausal osteoporosis

M. McClung, 2013 .

Role of bone-forming agents in the management of osteoporosis

M. McClung, 2021, Aging Clinical and Experimental Research.

A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab

Jacques P. Brown, A. Grauer, M. McClung, 2020, Osteoporosis International.

Assessing Fracture Risk in Individual Patients

M. McClung, Facp., 2007 .

Do current management strategies and guidelines adequately address fracture risk?

M. McClung, 2006, Bone.

Abaloparatide followed by alendronate in women ≥80 years with osteoporosis: post hoc analysis of ACTIVExtend

B. Mitlak, S. Greenspan, M. McClung, 2020, Menopause.

Effects of abaloparatide on bone mineral density and risk of fracture in postmenopausal women aged 80 years or older with osteoporosis

P. Miller, M. McClung, N. Harvey, 2018, Menopause.

Pathophysiology of Fractures

M. McClung, 2004 .

A Pooled Analysis of Fall Incidence From Placebo‐Controlled Trials of Denosumab

S. Cummings, R. Eastell, E. McCloskey, 2020, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Invasive Oral Procedures and Events in Postmenopausal Women With Osteoporosis Treated With Denosumab for Up to 10 Years.

N. Watts, N. Binkley, M. McClung, 2019, The Journal of clinical endocrinology and metabolism.

Observations following discontinuation of long-term denosumab therapy

P. Miller, M. McClung, E. Lewiecki, 2017, Osteoporosis International.

Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis

M. Brandi, D. Hans, J. Zanchetta, 2017, Osteoporosis International.

Denosumab for the treatment of osteoporosis

M. McClung, 2017, Osteoporosis and sarcopenia.

Chapter 83 – Denosumab for the Treatment of Osteoporosis

M. McClung, 2013 .

Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial

P. Miller, M. Peacock, M. McClung, 2012, Osteoporosis International.

An updated hip fracture incidence rate for Brazil: the Brazilian Validation Osteoporosis Study (BRAVOS)

J. Kanis, E. McCloskey, M. McClung, 2022, Archives of Osteoporosis.

Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group.

D. Kiel, T. Schnitzer, D. Felsenberg, 2000 .

Bisphosphonate therapy: To stop or not to stop?

M. McClung, 2007 .

Risedronate reduces hip fractures in patients with low femoral neck bone mineral density

J. Reginster, R. Eastell, P. Miller, 1999 .

The FRAX-based Lebanese osteoporosis treatment guidelines: rationale for a hybrid model

W. Leslie, A. Cheung, G. Fuleihan, 2016, Osteoporosis International.

Multisite bone ultrasound measurement on North American female reference population.

H. Genant, N. Watts, C. Njeh, 2001, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss.

R. Recker, P. Miller, M. McClung, 2009, Bone.

Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three‐year continued therapy and resolution of effect

R. Rizzoli, I. Reid, J. Eisman, 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Osteoporosis from the Perspective of an Endocrinologist

M. McClung, 1996 .

Odanacatib in postmenopausal women with low bone mineral density: a review of current clinical evidence

C. Zerbini, M. McClung, 2013, Therapeutic advances in musculoskeletal disease.

Risedronate Once A Week

M. McClung, 2003 .

Relation between body composition and biochemical markers of bone turnover among early postmenopausal women.

P. Ross, J. Davis, R. Wasnich, 2000, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study.

C. Christiansen, D. Hosking, M. McClung, 1999, The Journal of clinical endocrinology and metabolism.

Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling.

H. Genant, P. Delmas, K. Ensrud, 1995, The American journal of medicine.

Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double‐Blind, Phase 2, Parallel Group Study

Jacques P. Brown, A. Díez-Pérez, A. Grauer, 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group.

C. Christiansen, P. Ross, C. Chilvers, 1998, The New England journal of medicine.

Incidence of Hip and Subtrochanteric/Femoral Shaft Fractures in Postmenopausal Women With Osteoporosis in the Phase 3 Long‐Term Odanacatib Fracture Trial

M. Bouxsein, D. Dempster, Toshitaka Nakamura, 2021, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

The role of osteoanabolic agents in the management of patients with osteoporosis

P. Miller, M. McClung, E. Lewiecki, 2022, Postgraduate medicine.

Serum protein concentrations and bone mineral content in aging normal men.

D. Meier, R. Weigel, E. Orwoll, 1987, The American journal of clinical nutrition.

Risedronate in the Treatment of Paget's Disease of Bone: An Open Label, Multicenter Study

Jacques P. Brown, R. Altman, E. Siris, 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism

D. Bauer, T. Clemens, J. Bilezikian, 2009 .

Metabolic bone disease in asymptomatic men after partial gastrectomy with Billroth II anastomosis.

D. Meier, D. Lieberman, A. Parfitt, 1987, Gastroenterology.

Effects of pioglitazone on bone in postmenopausal women with impaired fasting glucose or impaired glucose tolerance: a randomized, double-blind, placebo-controlled study.

Alfonso T. Perez, R. Lindsay, M. McClung, 2013, The Journal of clinical endocrinology and metabolism.

FAMILIAL HYPERCHOLESTEROLAEMIA AND PRIMARY HYPOTHYROIDISM: COEXISTENCE OF BOTH DISORDERS IN A YOUNG WOMAN WITH SEVERE HYPERCHOLESTEROLAEMIA

D. Illingworth, M. McClung, W. Connor, 1981, Clinical endocrinology.

The Long-Term Effect Of Specific Type II 5α-Reductase Inhibition With Finasteride on Bone Mineral Density in Men: Results of a 4-Year Placebo Controlled Trial

D. Kadmon, J. Waldstreicher, M. McClung, 2002 .

Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: a double-blind, placebo-controlled, dose-ranging trial.

D. Kiel, R. Lindsay, M. McClung, 2007, The Journal of clinical endocrinology and metabolism.

Calcium and cholecalciferol: effects of small supplements in normal men.

R. Weigel, E. Orwoll, S. Oviatt, 1988, The American journal of clinical nutrition.

Executive Summary- Lebanese FRAX-Based Osteoporosis Guidelines 2013

J. Kanis, A. Cheung, G. Fuleihan, 2013 .

Looking for answers in all the wrong places.

M. McClung, 2007, Menopause.

The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program.

D. Reid, D. Black, E. Orwoll, 2010, Journal of the American Dental Association.

Body Size Accounts for Most Differences in Bone Density Between Asian and Caucasian Women

C. Coupland, P. Ross, R. Wasnich, 1996, Calcified Tissue International.

a repository copy of Pharmacologic intervention for prevention of fractures in osteopenic and osteoporotic postmenopausal women: Systemic review and meta-analysis

C. Cooper, J. Kanis, E. McCloskey, 2020 .

The efficacy of 48-week oral ibandronate treatment in postmenopausal osteoporosis when taken 30 versus 60 minutes before breakfast.

C. Christiansen, L. Tankó, M. McClung, 2003, Bone.

Quantitative ultrasound of the heel: Correlation with densitometric measurements at different skeletal sites

M. McClung, K. Faulkner, L. Coleman, 2006, Osteoporosis International.

Blood pressure and calcium intake are related tobone density in adult males

D. McCarron, M. McClung, C. Morris, 1999, British Journal of Nutrition.

Proceedings of the 2022 Santa Fe Bone Symposium: Current Concepts in the Care of Patients with Osteoporosis and Metabolic Bone Diseases.

M. Bouxsein, J. Bilezikian, P. Miller, 2022, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Bone density recovery after depot medroxyprogesterone acetate injectable contraception use.

M. McClung, A. Kaunitz, R. Arias, 2008, Contraception.

OP0248 Inhibition of Sclerostin with Romosozumab in Postmenopausal Women with Low Bone Mineral Density: Phase 2 Trial Results

Jacques P. Brown, S. Boonen, A. Díez-Pérez, 2013 .

Osteology: Further Debate

M. Drezner, R. Marcus, S. Khosla, 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Skeletal responses to romosozumab after 12 months of denosumab

Jacques P. Brown, J. Reginster, A. Chines, 2021, JBMR plus.

Hyperparathyroidism and pregnancy.

E. Orwoll, M. McClung, D. Lowe, 1947, American journal of surgery.

ZOLEDRONOVAYa KISLOTA V PROFILAKTIKE POTERI KOSTNOY TKANI U zhENShchIN POSTMENOPAUZAL'NOGO VOZRASTA S OSTEOPENIEY

C. Benhamou, P. Miller, P. Mesenbrink, 2011 .

Drug holidays in women treated for postmenopausal osteoporosis.

M. McClung, 2018, Menopause.

Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.

T. Schnitzer, D. Krupa, K. Cerchio, 2001, The Journal of clinical endocrinology and metabolism.

Creation of an age-adjusted, dual-energy x-ray absorptiometry-derived trabecular bone score curve for the lumbar spine in non-Hispanic US White women.

D. Hans, R. Winzenrieth, M. McClung, 2014, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

The long-term effect of specific type II 5alpha-reductase inhibition with finasteride on bone mineral density in men: results of a 4-year placebo controlled trial.

D. Kadmon, J. Waldstreicher, M. McClung, 2002, The Journal of urology.

Current bone mineral density data on bisphosphonates in postmenopausal osteoporosis.

M. McClung, 1996, Bone.

Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers.

D. Kimmel, R. Weinstein, W. Polvino, 1997, The Journal of clinical endocrinology and metabolism.

Bone mineral density in women aged 25-35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation.

P. Miller, M. McClung, A. Kaunitz, 2006, Contraception.

REINVIGORATING THE OSTEOPOROSIS MESSAGE.

M. McClung, 2016, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Effects of E2/P4 oral capsules on bone turnover in women with vasomotor symptoms

M. McClung, G. Constantine, R. Kagan, 2020, Menopause.

Standardization of femoral neck T-scores from hologic and lunar DXA systems

M. McClung, K. Faulkner, 2006, Osteoporosis International.

Management of postmenopausal osteoporosis: position statement of the North American Menopause Society.

B. Ettinger, M. McClung, R. Kagan, 2002, Menopause.

Two‐Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD

P. Miller, M. McClung, E. Lewiecki, 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

The 2017 hormone therapy position statement of The North American Menopause Society

J. Manson, L. Nelson, H. Hodis, 2017, Menopause.

A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial.

J. Reginster, E. Orwoll, P. Miller, 2015, The Journal of clinical endocrinology and metabolism.

A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density.

J. Reginster, S. Boonen, A. Grauer, 2012, The Journal of clinical endocrinology and metabolism.

Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk.

S. Cummings, O. Tørring, S. Boonen, 2011, The Journal of clinical endocrinology and metabolism.

American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis.

N. Watts, J. Bilezikian, M. Kleerekoper, 2010, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use.

D. Bauer, D. Dempster, E. Orwoll, 2005, Endocrine reviews.

Osteoporosis in men: epidemiology, diagnosis, prevention, and treatment.

Jacques P. Brown, S. Cummings, J. Adachi, 2004, Clinical therapeutics.

Therapeutic equivalence of alendronate 70 mg onceweekly and alendronate 10 mg daily in the treatment of osteoporosis

D. Kiel, T. Schnitzer, D. Felsenberg, 2000, Aging.

Proceedings of the 2017 Santa Fe Bone Symposium: Insights and Emerging Concepts in the Management of Osteoporosis.

C. Gordon, J. Bilezikian, P. Miller, 2018, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Dose-Response Relationships for Alendronate Treatment in Osteoporotic Elderly Women

D. Kimmel, R. Weinstein, W. Polvino, 1997 .

Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass.

G. Dalsky, D. Donley, J. S. San Martin, 2005, Archives of internal medicine.

Odanacatib, a cathepsin‐K inhibitor for osteoporosis: A two‐year study in postmenopausal women with low bone density

J. Eisman, R. Recker, C. Roux, 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Mid-molecule parathyroid hormone assay comparison.

E. Orwoll, M. McClung, J. Swanson, 1986, Clinical biochemistry.

Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards

C. Cooper, S. Silverman, O. Bruyère, 2011, Osteoporosis International.

Denosumab Rapidly Increases Cortical Bone in Key Locations of the Femur: A 3D Bone Mapping Study in Women With Osteoporosis

Andrew H Gee, Graham M Treece, Graham M. Treece, 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial

J. Eisman, D. Dempster, Toshitaka Nakamura, 2014, Osteoporosis International.

Romosozumab in postmenopausal women with low bone mineral density

Cesar Libanati, Steven Boonen, Michael R McClung, 2014, The New England journal of medicine.

Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.

D. Kiel, M. Sabatine, J. Reginster, 2019, The lancet. Diabetes & endocrinology.

Technetium-thallium scintiscanning for localization of parathyroid adenomas and hyperplasia. A reappraisal.

M. McClung, D. Lowe, K. Swartz, 1987, American journal of surgery.

American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003.

H. Rodbard, N. Watts, R. Recker, 2003, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Serum 25‐Hydroxyvitamin D Levels: Variability, Knowledge Gaps, and the Concept of a Desirable Range

C. Cooper, R. Bouillon, B. Clarke, 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Denosumab in Postmenopausal Women with Low Bone Mineral Density

P. Miller, M. Peacock, M. McClung, 2007 .

Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo‐Controlled FREEDOM Trial and Its Extension

Jacques P. Brown, S. Cummings, R. Eastell, 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis

S. Cummings, R. Rizzoli, S. Boonen, 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Vertebral Fractures: Clinical Importance and Management.

D. Bauer, J. Schousboe, P. Miller, 2016, The American journal of medicine.

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial.

J. S. San Martin, P. Miller, M. McClung, 2008, Bone.

Osteoporosis

W. Leslie, J. Compston, M. McClung, 1996, The Lancet.

Geography of Fracture Incidence in Postmenopausal Women with Osteoporosis Treated with Abaloparatide

P. Miller, M. McClung, G. Hattersley, 2017, Calcified Tissue International.

Diagnosis and management of osteoporosis in postmenopausal women: clinical guidelines. International Committee for Osteoporosis Clinical Guidelines.

R. Rizzoli, R. Eastell, P. Delmas, 1999, Clinical therapeutics.

Enhanced precision with dual-energy x-ray absorptiometry

H. Genant, R. Mazess, M. McClung, 1992, Calcified Tissue International.

Proceedings of the 2018 Santa Fe Bone Symposium: Advances in the Management of Osteoporosis.

P. Kostenuik, S. Khosla, L. Giangregorio, 2019, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Effects of denosumab on bone turnover markers in postmenopausal osteoporosis

S. Cummings, C. Christiansen, I. Reid, 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Effects of denosumab on fracture and bone mineral density by level of kidney function

S. Cummings, S. Boonen, S. Jamal, 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Proceedings of the 2015 Santa Fe Bone Symposium: Clinical Applications of Scientific Advances in Osteoporosis and Metabolic Bone Disease.

R. Baron, W. Leslie, J. Bilezikian, 2016, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Bone Health and Hormonal Contraception

M. McClung, A. Kaunitz, M. Dragoman, 2014 .

Discussion: Newer bisphosphonates in the treatment of paget's disease of bone: Where we are and where we want to go

E. McCloskey, A. Grauer, S. Wallach, 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Tiludronate therapy for Paget's disease of bone.

M. McClung, M R McClung, C K Tou, 1995, Bone.

Inhibition of RANKL as a treatment for osteoporosis: Preclinical and early clinical studies

M. McClung, 2006, Current osteoporosis reports.

The relationship of swimming exercise to bone mass in men and women.

K Huntington, E. Orwoll, S. Oviatt, 1989, Archives of internal medicine.

Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society

J. Manson, S. Silverman, V. Henderson, 2006, Menopause.

Cost effectiveness of romosozumab versus teriparatide for severe postmenopausal osteoporosis in Japan

S. Silverman, H. Hagino, M. McClung, 2021, Osteoporosis International.

Changes in bone density and turnover after alendronate or estrogen withdrawal

C. Christiansen, Y. Bagger, P. Alexandersen, 2004, Menopause.

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS- 2020 UPDATE EXECUTIVE SUMMARY.

N. Watts, Rachel Pessah-Pollack, N. Binkley, 2020, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Zoledronic Acid for the Prevention of Bone Loss in Postmenopausal Women With Low Bone Mass: A Randomized Controlled Trial

C. Benhamou, P. Mesenbrink, M. McClung, 2009, Obstetrics and gynecology.

A national random survey of bone mineral density reporting in the United States.

M. McClung, G. E. El-Hajj Fuleihan, J. Stock, 2002, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Osteoporosis update from the 2012 Santa Fe Bone Symposium.

M. Bouxsein, R. Marcus, J. Bilezikian, 2013, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Effects of risedronate on fracture risk in postmenopausal women with osteopenia

A. Grauer, E. Siris, I. Barton, 2007, Osteoporosis International.

Discrepancies in normative data between Lunar and Hologic DXA systems

M. McClung, K. Faulkner, L. A. Roberts, 2005, Osteoporosis International.

Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures

S. Cummings, C. Christiansen, E. Vittinghoff, 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Oral Daily Ibandronate Prevents Bone Loss in Early Postmenopausal Women Without Osteoporosis

J. Cauley, K. Ensrud, R. Recker, 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Revisiting the prevention of bone loss at menopause.

M. McClung, 2012, Menopause.

The Efficacy and Tolerability of Risedronate Once a week for the Treatment of Postmenopausal Osteoporosis

Jacques P. Brown, R. Lindsay, J. Adachi, 2002, Calcified Tissue International.

Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial.

C. Coupland, J. Davis, M. McClung, 1999, Annals of internal medicine.

Denosumab significantly increases DXA BMD at both trabecular and cortical sites: results from the FREEDOM study.

M. Brandi, P. Lakatos, A. Høiseth, 2011, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Femoral and Vertebral Strength Improvements in Postmenopausal Women With Osteoporosis Treated With Denosumab

Jacques P. Brown, H. Genant, R. Eastell, 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Femoral strength in osteoporotic women treated with teriparatide or alendronate.

T. Keaveny, B. Mitlak, D. Kopperdahl, 2012, Bone.

Bone Mineral Density After Transitioning From Denosumab to Alendronate

P. Ebeling, A. Chines, M. McClung, 2019, The Journal of clinical endocrinology and metabolism.

Application of the 1994 WHO classification to populations other than postmenopausal Caucasian women: the 2005 ISCD Official Positions.

N. Watts, W. Leslie, P. Miller, 2006, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Correction to: Geography of Fracture Incidence in Postmenopausal Women with Osteoporosis Treated with Abaloparatide

P. Miller, M. McClung, G. Hattersley, 2018, Calcified Tissue International.

Denosumab Reduces Cortical Porosity of the Proximal Femoral Shaft in Postmenopausal Women With Osteoporosis

A. Høiseth, J. Zanchetta, M. McClung, 2016, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate

C. Cooper, J. Reginster, D. Felsenberg, 2006, Osteoporosis International.

Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years

R. Recker, D. Wenderoth, M. McClung, 2012, Osteoporosis International.

N. Watts, Rachel Pessah-Pollack, N. Binkley, 2020, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

History of risedronate.

M. McClung, F. Ebetino, 2020, Bone.

Erratum to: Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial

J. Eisman, D. Dempster, S. Greenspan, 2015, Osteoporosis International.

Reducing hip fracture risk with risedronate in elderly women with established osteoporosis

P. Geusens, M. McClung, T. Masud, 2009, Clinical interventions in aging.

Safety and Efficacy of Risedronate in Reducing Fracture Risk in Osteoporotic Women Aged 80 and Older: Implications for the Use of Antiresorptive Agents in the Old and Oldest Old

Steven Boonen, Michael R McClung, Richard Eastell, 2004, Journal of the American Geriatrics Society.

Pins and plaster aren't enough: a call for the evaluation and treatment of patients with osteoporotic fractures.

T. Schnitzer, M. Hochberg, D. Black, 2003, The Journal of clinical endocrinology and metabolism.

Prevention and management of osteoporosis

Michael R McClung, M. McClung, 2003 .

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS MEDICAL GUIDELINES FOR CLINICAL PRACTICE FOR THE PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS: 2001 EDITION, WITH SELECTED UPDATES FOR 2003* AACE Osteoporosis Task Force Chairmen

R. Recker, R. Lindsay, J. Bilezikian, 2003 .

Review of risedronate in the treatment of osteoporosis

P. Geusens, M. McClung, 2001, Expert opinion on pharmacotherapy.

Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women.

H. Genant, K. Ensrud, M. McClung, 1997, The American journal of medicine.

Assessing fracture risk and effects of osteoporosis drugs: bone mineral density and beyond.

D. Bauer, D. Dempster, M. McClung, 2009, The American journal of medicine.

European guidance for osteoporosis: an American perspective.

M. McClung, 2008, Polskie Archiwum Medycyny Wewnetrznej.

Clinical utility of bone mass measurements in adults: consensus of an international panel. The Society for Clinical Densitometry.

H K Genant, R R Recker, J Dequeker, 1996, Seminars in arthritis and rheumatism.

The relationship between bone mineral density and fracture risk

M. McClung, 2005, Current osteoporosis reports.

Development and Validation of the Mini-Osteoporosis Quality of Life Questionnaire (OQLQ) in Osteoporotic Women with Back Pain due to Vertebral Fractures. Osteoporosis Quality of Life Study Group

G. Guyatt, L. Griffith, R. Epstein, 1999, Osteoporosis International.

Bone age as a correction factor for the analysis of trabecular bone score (TBS) in children

R. Winzenrieth, M. McClung, P. Clark, 2019, Archives of Osteoporosis.

Treatment With Once‐Weekly Alendronate 70 mg Compared With Once‐Weekly Risedronate 35 mg in Women With Postmenopausal Osteoporosis: A Randomized Double‐Blind Study

M. Hochberg, C. Rosen, M. McClung, 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Assessment of bone status using speed of sound at multiple anatomical sites.

H K Genant, C F Njeh, H. Genant, 2001, Ultrasound in medicine & biology.

Proceedings of the 2019 Santa Fe Bone Symposium: New Concepts in the Care of Osteoporosis and Rare Bone Diseases.

N. Watts, J. Bilezikian, D. Krakow, 2019, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Overdiagnosis and Overtreatment of Osteoporosis: A Wolf in Sheep's Clothing

M. McClung, 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Excretion of Sweat and Urine Pyridinoline Crosslinks in Healthy Controls and Subjects with Established Metabolic Bone Disease

B. Drinkwater, E. Schwartz, R. Recker, 2001, Clinical chemistry and laboratory medicine.

Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet

R. Recker, C. Benhamou, P. Miller, 2011, Osteoporosis International.

Assessment of mortality in patients enrolled in a risedronate clinical trial program: a retrospective cohort study.

A. Hofman, R. D'Agostino, A. Stemhagen, 2002, Regulatory toxicology and pharmacology : RTP.

Automated evaluation of hip axis length for predicting hip fracture

S. Cummings, M. McClung, K. Faulkner, 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

The bone and mineral manual : a practical guide

E. Siris, M. Kleerekoper, M. McClung, 1999 .

Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis.

S. Boonen, P. Delmas, C. Benhamou, 2008, Bone.

In postmenopausal women with osteoporosis, denosumab significantly improved trabecular bone score (TBS), an index of trabecular microarchitecture

J. Kaufman, M. Brandi, J. Zanchetta, 2012 .

Bone Mineral Density and Parathyroid Hormone as Independent Risk Factors for Mortality in Community‐Dwelling Older Adults: A Population‐Based Prospective Cohort Study in Brazil. The São Paulo Ageing & Health (SPAH) Study

M. Scazufca, M. McClung, C. Figueiredo, 2016, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

The Efficacy and Tolerability of a Monthly Dosing Regimen of 75mg Risedronate Dosed on 2 Consecutive Days a Month for the Treatment of Postmenopausal Women with Osteoporosis – 2 Year Study Results

R. Recker, C. Benhamou, J. Zanchetta, 2009 .

Nonpharmacologic Therapy for Osteoporosis

M. McClung, Kristin Spencer, 1996 .

Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women

S. Cummings, C. Christiansen, T. Powles, 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Treatment rates and healthcare costs of patients with fragility fracture by site of care: a real-world data analysis

M. McClung, A. Singer, S. Goldstein, 2023, Archives of Osteoporosis.

Denosumab densitometric changes assessed by quantitative computed tomography at the spine and hip in postmenopausal women with osteoporosis.

Jacques P. Brown, M. Brandi, E. Franek, 2013, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Premature osteoporosis in multiple sclerosis implications for corticosteroid therapy

D. Bourdette, M. McClung, R. Whitham, 1990 .

An update on osteoporosis pathogenesis, diagnosis, and treatment.

R. Baron, M. Bouxsein, M. McClung, 2017, Bone.

Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.

R. Recker, M. McClung, A. Kriegman, 2007, Bone.

Therapeutic approaches to bone protection in adulthood

J. Compston, M. McClung, E. Curtis, 2018 .

Postmenopausal osteoporosis: fracture risk and prevention.

M. McClung, S. Wysocki, A. Kaunitz, 2009, Journal of Family Practice.

Efficacy of odanacatib in postmenopausal women with osteoporosis: subgroup analyses of data from the phase 3 long-term odanacatib fracture trial (LOFT)

P. Alexandersen, C. Benhamou, K. Saag, 2016 .

A Novel Monthly Dosing Regimen of Risedronate for the Treatment of Postmenopausal Osteoporosis: 2-Year Data

P. Delmas, R. Recker, C. Benhamou, 2012, Calcified Tissue International.

Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data

S. Boonen, P. Delmas, C. Roux, 2012, Osteoporosis International.

Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results

P. Delmas, R. Recker, C. Benhamou, 2008, Osteoporosis International.

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/ AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS- 2020 UPDATE.

N. Watts, Rachel Pessah-Pollack, N. Binkley, 2021, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Official positions of the International Society for Clinical Densitometry.

N. Watts, J. Shepherd, L. Bachrach, 2004, Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA.

Controversial issues in climacteric medicine IV Postmenopausal osteoporosis: therapeutic options

C. Christiansen, C. Campagnoli, J. Kanis, 2005 .

Practice guidelines on the use of bone mineral density measurements: Who to test? What measures to use? When to treat? A consensus report from the Middle East Densitometry Workshop.

M. McClung, H. Awada, G. E. El-Hajj Fuleihan, 2002, Le Journal medical libanais. The Lebanese medical journal.

Official positions of the International Society for Clinical Densitometry.

N. Watts, J. Shepherd, L. Bachrach, 2004, Southern medical journal.

OP0251 Effects of 2 Years of Treatment with Romosozumab Followed by 1 Year of Denosumab or Placebo in Postmenopausal Women with Low Bone Mineral Density

A. Díez-Pérez, A. Grauer, A. Chines, 2015 .

Romosozumab Efficacy in Postmenopausal Women With No Prior Fracture Who Fulfill Criteria for Very High Fracture Risk.

M. McClung, F. Cosman, C. Deignan, 2023, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Denosumab densitometric changes assessed by quantitative computed tomography at the spine and hip in postmenopausal women with osteoporosis.

Jacques P. Brown, M. Brandi, E. Franek, 2013, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Measurement of body composition in the elderly: dual energy x-ray absorptiometry, underwater weighing, bioelectrical impedance analysis, and anthropometry.

M. McClung, G. Brodowicz, S. Althoff, 1994, Gerontology.

Serum 25‐Hydroxyvitamin D Levels: Variability, Knowledge Gaps, and the Concept of a Desirable Range

C. Cooper, R. Bouillon, M. McClung, 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Should vitamin D supplements be prescribed routinely for midlife women?

M. McClung, 2022, Menopause.

EFFECT OF FLUTICASONE PROPIONATE/SALMETEROL COMBINATION ON CHANGE IN BONE MINERAL DENSITY IN SUBJECTS WITH COPD

R. Zuwallack, M. McClung, C. Fogarty, 2008 .

Osteoporosis update from the 2010 santa fe bone symposium.

R. Marcus, N. Watts, S. Khosla, 2011, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

H. Rodbard, N. Watts, R. Recker, 2003, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

THURSDAY CONCURRENT SESSION # 1 S-1 . Odanacatib Efficacy and Safety in Postmenopausal Women with Osteoporosis : 5-Year Data from the Extension of the Phase 3 Long-term Odanacatib Fracture Trial ( LOFT )

D. Kiel, J. Manson, J. Cauley, 2016 .

Clinical Interventions in Aging Dovepress Open Access to Scientific and Medical Research Open Access Full Text Article Reducing Hip Fracture Risk with Risedronate in Elderly Women with Established Osteoporosis

P. Geusens, M. McClung, T. Masud, 2022 .

American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis.

N. Watts, J. Bilezikian, M. Kleerekoper, 2010, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Effects of denosumab on bone turnover markers in postmenopausal osteoporosis

S. Cummings, C. Christiansen, I. Reid, 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Geography of Fracture Incidence in Postmenopausal Women with Osteoporosis Treated with Abaloparatide

P. Miller, M. McClung, G. Hattersley, 2017, Calcified Tissue International.

Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis

S. Cummings, R. Rizzoli, S. Boonen, 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.